MedTrace Logo

Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

NCT05886933 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9846

Last updated 2025-01-24

No results posted yet for this study

Summary

This observational study is a large-scale, prospective, and multi-institutional observational study.

Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Fexuprazan Hydrochloride

Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Homin Lee · Co&Ping Otolaryngology Clinic

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2024-04-30
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886933 on ClinicalTrials.gov